In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms
Keynote lecture: Optimising adjuvant treatment in HR+/HER2 negative early breast cancer
3 May 2022, 15:40-16:10, Berlin Hall
Special session on the Ukraine: How many wars to fight?
4 May 2022, 11:35-12:20, Cologne Hall
Keynote lecture: How shall our knowledge of cancer evolution transform breast oncology?
4 May 2022, 14:10-14:40, Berlin Hall
The value of genomic testing is being increasingly demonstrated and will evolve over time
Results suggest the efficacy of trastuzumab deruxtecan is influenced by the spatial distribution of HER2 in breast tumour cells
A translational analysis of the DAISY trial improves knowledge on the mechanisms of action of the antibody–drug conjugate
Combining PARP1 inhibition with an ATR inhibitor does not improve outcomes in pre-treated metastatic TNBC
Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent
Two studies hint at a lack of effect of palbociclib on ovarian function and demonstrate similar reduced recurrence with abemaciclib regardless of menopausal status
In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer